rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-357-364rsp-3782Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHПоказатели цитокинового профиля у пациентов с системной красной волчанкой: взаимосвязь с активностью заболевания и уровнем аутоантител (предварительные результаты)Cytokine profile in patients with systemic lupus erythematosus: Relationship with disease activity and autoantibody levels (preliminary results)https://orcid.org/0000-0003-3057-9175АвдееваА. С.AvdeevaA. S.

Авдеева Анастасия Сергеевна

115522, Каширское шоссе, 34а

Anastasia S. Avdeeva

115522, Moscow, Kashirskoye Highway, 34A

9056249400@mail.ruhttps://orcid.org/0000-0001-6404-0042ДиатроптовМ. Е.DiatroptovM. E.

115522, Каширское шоссе, 34а

Mikhail E. Diatroptov

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-2024-6927ГорбуноваЮ. Н.GorbunovaYu. N.

115522, Каширское шоссе, 34а

Yulia N. Gorbunova

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-5793-4689ПопковаТ. В.PopkovaT. V.

115522, Каширское шоссе, 34а

Tatiana V. Popkova

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-1053-6952ПанафидинаТ. А.PanafidinaT. A.

115522, Каширское шоссе, 34а

Tatiana A. Panafidina

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Каширское шоссе, 34а

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202531082025634357364Copyright © Авдеева А.С., Диатроптов М.Е., Горбунова Ю.Н., Попкова Т.В., Панафидина Т.А., Насонов Е.Л., 20252025Авдеева А.С., Диатроптов М.Е., Горбунова Ю.Н., Попкова Т.В., Панафидина Т.А., Насонов Е.Л.Avdeeva A.S., Diatroptov M.E., Gorbunova Y.N., Popkova T.V., Panafidina T.A., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3782

Цель исследования – изучить сывороточный уровень цитокинов, хемокинов, факторов роста у пациентов с системной красной волчанкой (СКВ) в сравнении со здоровыми добровольцами для выявления перспективных показателей, более точной оценки активности заболевания и развития органных поражений.

Материал и методы

Материал и методы. В анализ было включено 139 пациентов (123 (88%) женщины и 16 (12%) мужчин) с достоверным диагнозом СКВ. Медиана длительности заболевания составила 3,0 [0,3; 12,0] года, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) – 7 [4; 11] баллов, SDI (SLICC (Systemic Lupus International Collaborating Clinics) Damage Index) – 0 [0; 1] баллов. Исследование 48 цитокинов в сыворотке крови осуществляли методом мультиплексного иммунного анализа на основе суспензионной микрочиповой технологии хМАР (Bio-Plex® 200 Pro Human Cytokine Screening Panel, 48-Plex; Bio-Rad Laboratories, США) согласно инструкциям фирмы-производителя. Контрольную группу составили 13 здоровых доноров, сопоставимых по полу и возрасту с обследованными больными.

Результаты

Результаты. У пациентов с СКВ по сравнению со здоровыми донорами отмечался более высокий уровень гранулоцитарного колониестимулирующего фактора (Г-КСФ), интерферона (ИФН) γ, интерлейкина (ИЛ) 6, ИЛ-8, моноцитарного хемотаксического протеина (MCP, monocyte chemotactic protein) 1, антагониста рецептора ИЛ-1 (ИЛ-1Ра), макрофагального воспалительного протеина (MIP, macrophage inflammatory protein) 1α, сосудистого эндотелиального фактора роста (СЭФР), ИЛ-18, IP-10 (interferon-inducible protein 10), LIF (leukemia inhibitory factor), MCP-3, макрофагального колониестимулирующего фактора (М-КСФ), MIG (monokine induced by IFN-γ) (p<0,05). В группе больных с нефритом (n=40) отмечалась более высокая концентрация ИФН-γ, ИЛ-7, СЭФР, ИФН-α2, макрофагального колониестимулирующего фактора (М-КСФ), в отличие от пациентов без нефрита (p<0,05).

Заключение

Заключение. В сыворотках пациентов с СКВ отмечается более высокий уровень провоспалительных цитокинов хемокинов, колониестимулирующих, стромальных и ангиогенных факторов; важную роль в развитии нефрита, вероятно, играет М-КСФ. Требуются дальнейшие исследования для улучшения наших представлений о роли показателей цитокинового профиля в патогенезе СКВ.

The aim – to study the serum level of cytokines, chemokines, growth factors in patients with systemic lupus erythematosus (SLE) in comparison with healthy volunteers to identify promising indicators for assessing disease activity and the development of organ damage.

Material and methods

Material and methods. The analysis included 139 patients (123 (88%) women and 16 (12%) men) with a reliable diagnosis of SLE. The median duration of the disease was 3.0 [0.3; 12.0] years, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) – 7 [4; 11] points, SDI (SLICC (Systemic Lupus International Collaborating Clinics) Damage Index) – 0 [0; 1] points. The study of 48 cytokines in blood serum was carried out by the method of multiplex immune analysis based on suspension microarray technology xMAP (Bio-Plex® 200 Pro Human Cytokine Screening Panel, 48-Plex; Bio-Rad Laboratories, USA) according to the manufacturer’s instructions. The control group consisted of 13 healthy donors, comparable in gender and age with the examined patients.

Results

Results. In patients with SLE, compared with healthy donors, there was a higher level of granulocyte colony-stimulating factor (G-CSF), interferon (IFN) γ, interleukin (IL) 6, IL-8, monocyte chemotactic protein (MCP) 1, IL-1 receptor antagonist (IL-1Ra), macrophage inflammatory protein (MIP) 1α, vascular endothelial growth factor (VEGF), IL-18, interferon-inducible protein 10 (IP-10), leukemia inhibitory factor (LIF), MCP-3, macrophage colony-stimulating factor (M-CSF), MIG (monokine induced by IFN-γ) (p<0.05). In the group of patients with nephritis (n=40), there was a higher concentration of IFN-γ, IL-7, VEGF, IFN-α2, M-CSF in contrast to patients without nephritis (p<0.05). Conclusion. In the sera of patients with SLE, a higher level of proinflammatory cytokines, chemokines, colony-stimulating, stromal and angiogenic factors is noted; M-CSF probably plays an important role in the development of nephritis. Further studies are required to improve our understanding of the role of cytokine profile parameters in the pathogenesis of SLE.

системная красная волчанкацитокиновый профильактивность заболеванияаутоантителаsystemic lupus erythematosuscytokine profiledisease activityautoantibodiesНастоящее исследование выполнено в рамках фундаментальной темы № 1021051402790-6 «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний»ReferencesNasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412Capecchi R, Puxeddu I, Pratesi F, Migliorini P. New biomarkers in SLE: From bench to bedside. Rheumatology (Oxford). 2020;59(Suppl 5):12-18. doi: 10.1093/rheumatology/keaa484Capecchi R, Puxeddu I, Pratesi F, Migliorini P. New biomarkers in SLE: From bench to bedside. Rheumatology (Oxford). 2020;59(Suppl 5):12-18. doi: 10.1093/rheumatology/keaa484Parodis I, Sjöwall C. Immune mechanisms and biomarkers in systemic lupus erythematosus. Int J Mol Sci. 2024;25(18):9965. doi: 10.3390/ijms25189965Parodis I, Sjöwall C. Immune mechanisms and biomarkers in systemic lupus erythematosus. Int J Mol Sci. 2024;25(18):9965. doi: 10.3390/ijms25189965Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: The challenging quest. Rheumatology (Oxford). 2017;56(Suppl 1):32-45. doi: 10.1093/rheumatology/kew407Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: The challenging quest. Rheumatology (Oxford). 2017;56(Suppl 1):32-45. doi: 10.1093/rheumatology/kew407Zharkova O, Celhar T, Cravens PD, Satterthwaite AB, Fairhurst AM, Davis LS. Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(Suppl 1):55-66. doi: 10.1093/rheumatology/kew427Zharkova O, Celhar T, Cravens PD, Satterthwaite AB, Fairhurst AM, Davis LS. Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(Suppl 1):55-66. doi: 10.1093/rheumatology/kew427Yap DI, Lai KN. The role of cytokines in the pathogenesis of systemic lupus erythematosis – From bench to bedside. Nephrology. 2013;(18):243-255. doi: 10.1111/nep.12047Yap DI, Lai KN. The role of cytokines in the pathogenesis of systemic lupus erythematosis – From bench to bedside. Nephrology. 2013;(18):243-255. doi: 10.1111/nep.12047Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi: 10.3390/biom11070928Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi: 10.3390/biom11070928Alduraibi FK, Tsokos G. Lupus nephritis biomarkers: A critical review. Int J Mol Sci. 2024;25(2):805. doi: 10.3390/ijms25020805Alduraibi FK, Tsokos G. Lupus nephritis biomarkers: A critical review. Int J Mol Sci. 2024;25(2):805. doi: 10.3390/ijms25020805Petri M, Stohl W, Chatham W, McCune W, Chevrier M, Ryel J, et al. Association of plasma, B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453-2459. doi: 10.1002/art.23678Petri M, Stohl W, Chatham W, McCune W, Chevrier M, Ryel J, et al. Association of plasma, B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453-2459. doi: 10.1002/art.23678Chun HY, Chung JW, Kim HA, Yun J, Jeon J, Ye Y, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;(27):461-466. doi: 10.1007/s10875-007-9104-0Chun HY, Chung JW, Kim HA, Yun J, Jeon J, Ye Y, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;(27):461-466. doi: 10.1007/s10875-007-9104-0Zhang S, Xu R, Kang L. Biomarkers for systemic lupus erythematosus: A scoping review. Immun Inflamm Dis. 2024:e70022. doi: 10.1002/iid3.70022Zhang S, Xu R, Kang L. Biomarkers for systemic lupus erythematosus: A scoping review. Immun Inflamm Dis. 2024:e70022. doi: 10.1002/iid3.70022Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H, et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016;(74):182-193. doi: 10.1016/j.jaut.2016.06.001Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H, et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016;(74):182-193. doi: 10.1016/j.jaut.2016.06.001Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xMiyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xНасонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017. [Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow:GEOTAR-Media;2017 (In Russ.)].Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow:GEOTAR-Media;2017 (In Russ.).Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-291.Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-291.Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-369. doi: 10.1002/art.1780390303Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-369. doi: 10.1002/art.1780390303Pacheco Y, Barahona-Correa J, Monsalve DM, Acosta-Ampudia Y, Rojas M, Rodríguez Y, et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med. 2017;15(1):239. doi: 10.1186/s12967-017-1345-yPacheco Y, Barahona-Correa J, Monsalve DM, Acosta-Ampudia Y, Rojas M, Rodríguez Y, et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med. 2017;15(1):239. doi: 10.1186/s12967-017-1345-yReynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E, et al. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018;20(1):173. doi: 10.1186/s13075-018-1666-0Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E, et al. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018;20(1):173. doi: 10.1186/s13075-018-1666-0Lindblom J, Beretta L, Borghi MO and PRECISESADS Clinical Consortium, Alarco´n-Riquelme ME, Parodis I. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. Front Immunol. 2023;30:14:1257085. doi: 10.3389/fimmu.2023.1257085Lindblom J, Beretta L, Borghi MO and PRECISESADS Clinical Consortium, Alarco´n-Riquelme ME, Parodis I. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. Front Immunol. 2023;30:14:1257085. doi: 10.3389/fimmu.2023.1257085Nasonov EL, Avdeeva AS. Interleukin 18 in immune-mediated rheumatic diseases and COVID-19. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(2):195-204 (In Russ.). doi: 10.47360/1995-4484-2022-195-204Nasonov EL, Avdeeva AS. Interleukin 18 in immune-mediated rheumatic diseases and COVID-19. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(2):195-204 (In Russ.). doi: 10.47360/1995-4484-2022-195-204Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. Analysis of serum interleukin (IL)-1beta and IL-18 in systemic lupus erythematosus. Front Immunol. 2018;9:1250. doi: 10.3389/fmmu.2018.01250Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. Analysis of serum interleukin (IL)-1beta and IL-18 in systemic lupus erythematosus. Front Immunol. 2018;9:1250. doi: 10.3389/fmmu.2018.01250Umare V, Pradhan V, Nath S, Rajadhyaksha A, Ghosh K, Nadkarni AH. Impact of functional IL-18 polymorphisms on genetic predisposition and diverse clinical manifestations of the disease in Indian SLE patients. Lupus. 2019;28:545-554. doi: 10.1177/0961203319834677Umare V, Pradhan V, Nath S, Rajadhyaksha A, Ghosh K, Nadkarni AH. Impact of functional IL-18 polymorphisms on genetic predisposition and diverse clinical manifestations of the disease in Indian SLE patients. Lupus. 2019;28:545-554. doi: 10.1177/0961203319834677Jafari-Nakhjavani MR, Abedi-Azar S, Nejati B. Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus. J Nephropathol. 2016;5:28-33. doi: 10.15171/jnp.2016.05Jafari-Nakhjavani MR, Abedi-Azar S, Nejati B. Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus. J Nephropathol. 2016;5:28-33. doi: 10.15171/jnp.2016.05Wu CY, Yang HY, Yao TC, Liu SH, Huang JL. Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients. Medicine. (2016);95:e5037. doi: 10.1097/MD.0000000000005037Wu CY, Yang HY, Yao TC, Liu SH, Huang JL. Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients. Medicine. (2016);95:e5037. doi:10.1097/MD.0000000000005037Hirooka Y, Nozaki Y. Interleukin-18 in inflammatory kidney disease. Front Med. 2021;8:639103. doi: 10.3389/fmed.2021.639103Hirooka Y, Nozaki Y. Interleukin-18 in inflammatory kidney disease. Front Med. 2021;8:639103. doi: 10.3389/fmed.2021.639103Xiang M, Feng Y, Wang Y. Wang J, Zhang Z, Liang J. Correlation between circulating interleukin‑18 level and systemic lupus erythematosus: A meta‑analysis. Sci Rep. 2021;11:4707. doi: 10.1038/s41598-021-84170-4Xiang M, Feng Y, Wang Y. Wang J, Zhang Z, Liang J. Correlation between circulating interleukin‑18 level and systemic lupus erythematosus: A meta‑analysis. Sci Rep. 2021;11:4707. doi: 10.1038/s41598-021-84170-4Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus. Front Immunol. 2018;9:1250. doi: 10.3389/fimu.2018.01250Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus. Front Immunol. 2018;9:1250. doi: 10.3389/fimu.2018.01250Ruchakorn N, Ngamjanyaporn P, Suangtamai T, Kafaksom T, Polpanumas C, Petpisit V. Performance of cytokine models in predicting SLE activity. Arthrit Res Ther. 2019;21:287. doi: 10.1186/s13075-019-2029-1Ruchakorn N, Ngamjanyaporn P, Suangtamai T, Kafaksom T, Polpanumas C, Petpisit V. Performance of cytokine models in predicting SLE activity. Arthrit Res Ther. 2019;21:287. doi: 10.1186/s13075-019-2029-1Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;55(4):452-461. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019-452-461Bauer J, Baechler E, Petri M, Batliwalla F, Crawford D, Ortmann W, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3(12):e491. doi: 10.1186/s13075-019-2029-1Bauer J, Baechler E, Petri M, Batliwalla F, Crawford D, Ortmann W, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3(12):e491. doi: 10.1186/s13075-019-2029-1Kirou K, Lee C, George S, Louca K, Peterson M, Crow M. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491-1503. doi: 10.1002/art.21031Kirou K, Lee C, George S, Louca K, Peterson M, Crow M. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491-1503. doi: 10.1002/art.21031Puapatanakul P, Chansritrakul S, Susantitaphong P, Ueaphongsukkit T, Eiam-Ong S, Praditpornsilpa K, et al. Interferon-inducible protein 10 and disease activity in systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis. Int J Mol Sci. 2019;20(19):4954. doi: 10.3390/ijms20194954Puapatanakul P, Chansritrakul S, Susantitaphong P, Ueaphongsukkit T, Eiam-Ong S, Praditpornsilpa K, et al. Interferon-inducible protein 10 and disease activity in systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis. Int J Mol Sci. 2019;20(19):4954. doi: 10.3390/ijms20194954Mirioğlu Ş, Çinar S, Uludağ Ö, Gürel E, Varelci S, Özlük Y. Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus. Turk J Med Sci. 2024;54(2):391-400. doi: 10.55730/1300-0144.5804Mirioğlu Ş, Çinar S, Uludağ Ö, Gürel E, Varelci S, Özlük Y. Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus. Turk J Med Sci. 2024;54(2):391-400. doi: 10.55730/1300-0144.5804Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, et al. Macrophage activation syndrome in systemic lupus erythematosus: A multicenter, case-control study in China. Clin Rheumatol. 2018;37:93-100. doi: 10.1007/s10067-017-3625-6Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, et al. Macrophage activation syndrome in systemic lupus erythematosus: A multicenter, case-control study in China. Clin Rheumatol. 2018;37:93-100. doi: 10.1007/s10067-017-3625-6Ayoub S, Hickey MJ, Morand EF. Mechanisms of disease: Macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Pract Rheumatol. 2008;4:98-105. doi: 10.1038/ncprheum0701Ayoub S, Hickey MJ, Morand EF. Mechanisms of disease: Macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Pract Rheumatol. 2008;4:98-105. doi: 10.1038/ncprheum0701Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythematosus. Discov Med. 2012;13:151-158.Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythematosus. Discov Med. 2012;13:151-158.Burbano C, Villar-Vesga J, Vasquez G, Muñoz-Vahos C, Rojas M, Castaño D. Proinflammatory differentiation of macrophages through microparticles that form immune complexes leads to Tand B-cell activation in systemic autoimmune diseases. Front Immunol. 2019;10:2058. doi: 10.3389/fimmu.2019.02058Burbano C, Villar-Vesga J, Vasquez G, Muñoz-Vahos C, Rojas M, Castaño D. Proinflammatory differentiation of macrophages through microparticles that form immune complexes leads to Tand B-cell activation in systemic autoimmune diseases. Front Immunol. 2019;10:2058. doi: 10.3389/fimmu.2019.02058Horuluoglu B, Bayik D, Kayraklioglu N, Goguet E, Kaplan MJ, Klinman DM. PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus. J Autoimmun. 2019;99:24-32. doi: 10.1016/j.jaut.2019.01.004Horuluoglu B, Bayik D, Kayraklioglu N, Goguet E, Kaplan MJ, Klinman DM. PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus. J Autoimmun. 2019;99:24-32. doi: 10.1016/j.jaut.2019.01.004Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili S, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425-6440. doi: 10.1002/jcp.26429Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili S, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425-6440. doi: 10.1002/jcp.26429Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GMCSF and M-CSF origin. Cell Immunol. 2013;281:51-61. doi: 10.1016/j.cellimm.2013.01.010Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GMCSF and M-CSF origin. Cell Immunol. 2013;281:51-61. doi: 10.1016/j.cellimm.2013.01.010Li F, Yang Y, Zhu X, Huang L, Xu J. Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem. 2015;37:1279-1288. doi: 10.1159/000430251Li F, Yang Y, Zhu X, Huang L, Xu J. Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem. 2015;37:1279-1288. doi: 10.1159/000430251Wen S, He F, Zhu X, Yuan S, Liu H, Sun L. IFN-gamma, CXCL16, uPAR: Potential biomarkers for systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36:36-43.Wen S, He F, Zhu X, Yuan S, Liu H, Sun L. IFN-gamma, CXCL16, uPAR: Potential biomarkers for systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36:36-43.Wang R, Zhao H, Liu Y, Li Y, Cai J. Macrophage colony-stimulating factor could evaluate both disease activity and renal involvement in systemic lupus erythematosus. Ann Palliat Med. 2021;10(2):2098-2107. doi: 10.21037/apm-20-2607Wang R, Zhao H, Liu Y, Li Y, Cai J. Macrophage colony-stimulating factor could evaluate both disease activity and renal involvement in systemic lupus erythematosus. Ann Palliat Med. 2021;10(2):2098-2107. doi: 10.21037/apm-20-2607Ragsdale ME, Hall Zimmerman LG. Use of colony-stimulating factors in patients with systemic lupus erythematosus. J Pharm Pract. 2023;36(3):719-724. doi: 10.1177/08971900211053268Ragsdale ME, Hall Zimmerman LG. Use of colony-stimulating factors in patients with systemic lupus erythematosus. J Pharm Pract. 2023;36(3):719-724. doi: 10.1177/08971900211053268

The authors declare that there are no conflicts of interest present.